Cytogenetic abnormalities and clinical outcome in Wilms tumor: A study by the UK Cancer Cytogenetics Group and the UK Children's Cancer Study Group

被引:46
作者
Bown, N
Cotterill, SJ
Roberts, P
Griffiths, M
Larkins, S
Hibbert, S
Middleton, H
Kelsey, A
Tritton, D
Mitchell, C
机构
[1] Newcastle Univ, Sch Biochem & Genet, Dept Human Genet, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England
[2] Newcastle Univ, Inst Child Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[3] St James Univ Hosp, Reg Cytogenet Unit, Leeds LS9 7TF, W Yorkshire, England
[4] Birmingham Womens Hosp, W Midland Reg Genet Serv, Birmingham, W Midlands, England
[5] Univ Leicester, UK Children Canc Study Grp, Ctr Data, Leicester, Leics, England
[6] Royal Manchester Childrens Hosp, Dept Pathol, Manchester M27 1HA, Lancs, England
[7] John Radcliffe Hosp, Dept Paediat Oncol, Oxford OX3 9DU, England
来源
MEDICAL AND PEDIATRIC ONCOLOGY | 2002年 / 38卷 / 01期
关键词
Wilms tumor; prognosis; chromosome; 1; 16; monosomy; 22;
D O I
10.1002/mpo.1258
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Tumor genetic features reported to correlate with adverse outcome in Wilms tumor include karyotype complexity, losses of material from the short arm of chromosome 1 and from the long arms of chromosomes 11, 16 and 22 and gain of Material from the long arm of chromosome 1. This study sought to test these associations in a large series of tumors studied by cytogenetic analysis. Identification of markers associated with elevated risk of relapse and fatal outcome could allow more effective treatment stratification at presentation, Procedure, Thirteen member laboratories of the U.K. Cancer Cytogenetics Group provided results from a 12-year period. Karyotype abnormalities were correlated with clinical data (age, tumor stage, and histology) and outcome data provided by the central register of the U.K. Children's Cancer Study Group. Results. Of 127 abnormal karyotypes, 78 included a reputedly "poor prognosis" feature. Univariate survival analysis showed no significant adverse effect for karyotype complexity, 1 p loss or 11 q loss. The poor outcome of cases with 16q loss was of borderline significance, but this effect was restricted to those tumors with unbalanced translocation der(16)t(1q;16q). The association between relapse risk and gain of 1q material was not significant. Only monosomy 22 was a significant marker of poor outcome in univariate analysis (13 cases showing 50% relapse free survival at 5 years compared to 79% survival for the remaining 114 cases, P=0.02), In multivariate analysis, significant independent predictors of poor outcome were 1q gain (Hazard Ratio 3.4), stage IV disease (HR 5.0), and monosomy 22 (HR 5.9). Conclusions. Loss of chromosome 22 identifies high risk Wilms tumors. The prognostic significance of 1q gain, 16q loss and unbalanced translocation der(16)t(1q;16q) is unresolved and warrants further investigation. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:11 / 21
页数:11
相关论文
共 30 条
[1]  
BECKWITH JB, 1978, CANCER-AM CANCER SOC, V41, P1937, DOI 10.1002/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO
[2]  
2-U
[3]   Trisomy 1q generating translocations in Wilms tumor [J].
Betts, DR ;
Ilg, EC ;
Oezahin, H ;
von der Weid, N ;
Niggli, FK .
CANCER GENETICS AND CYTOGENETICS, 1999, 112 (02) :138-143
[4]   HYPERDIPLOIDY AND CHROMOSOMAL REARRANGEMENTS DEFINE THE ANAPLASTIC VARIANT OF WILMS-TUMOR [J].
DOUGLASS, EC ;
LOOK, AT ;
WEBBER, B ;
PARHAM, D ;
WILIMAS, JA ;
GREEN, AA ;
ROBERSON, PK .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (06) :975-981
[5]   DIAGNOSTIC RELEVANCE OF CLONAL CYTOGENETIC ABERRATIONS IN MALIGNANT SOFT-TISSUE TUMORS [J].
FLETCHER, JA ;
KOZAKEWICH, HP ;
HOFFER, FA ;
LAGE, JM ;
WEIDNER, N ;
TEPPER, R ;
PINKUS, GS ;
MORTON, CC ;
CORSON, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (07) :436-442
[6]   Comparative genomic hybridization and its application to Wilms' tumorigenesis [J].
Getman, ME ;
Houseal, TW ;
Miller, GA ;
Grundy, PE ;
Cowell, JK ;
Landes, GM .
CYTOGENETICS AND CELL GENETICS, 1998, 82 (3-4) :284-290
[7]  
GRUNDY PE, 1994, CANCER RES, V54, P2331
[8]  
GRUNDY RG, 1998, BRIT J CANCER, V78, P1131
[9]  
Hattinger CM, 1996, GENE CHROMOSOME CANC, V17, P141, DOI 10.1002/(SICI)1098-2264(199611)17:3<141::AID-GCC1>3.0.CO
[10]  
2-4